Extended use of insomnia drug Circadin approved in EU
This article was originally published in Scrip
The European Commission has approved a change in treatment duration for Neurim Pharmaceuticals/Nycomed/Lundbeck's insomnia drug Circadin (melatonin), from three weeks to 13 weeks (three months), in patients aged 55 years and over with primary insomnia .
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.